Teva: We Have 16 Biosimilars In The Pipeline, Our Aim Is 20
Firm Says It Has ‘Good Manufacturing’ But Will Also Continue Partnership Model
A year into the job, Teva’s CEO Richard Francis returned to the J.P. Morgan Annual Healthcare Conference to discuss future investment in biosimilars and the importance of Teva’s long-acting injectable programs.
You may also be interested in...
The company also announced plans to divest its active pharmaceutical ingredients (API) business as part of its ‘Pivot to Growth’ strategy.
US adalimumab biosimilars could soon see increased uptake after CVS Caremark announced plans to remove the Humira brand from its major national formularies entirely, in favor of biosimilars.
Teva has announced a new investment from Royalty Pharma in its long-acting injectable formulation of olanzapine that is being developed for the US market with partner MedinCell.